Editorial
doi: 10.1016/j.jhep.2008.07.003.
Epub 2008 Jul 18.
Is there discrimination in access to therapy for HCV patients?
- PMID: 18678432
- DOI: 10.1016/j.jhep.2008.07.003
Item in Clipboard
Editorial
Is there discrimination in access to therapy for HCV patients?
J Hepatol.
2008 Oct.
Free article
No abstract available
Comment on
-
Market uptake of new antiviral drugs for the treatment of hepatitis C.J Hepatol. 2008 Oct;49(4):528-36. doi: 10.1016/j.jhep.2008.04.021. Epub 2008 Jun 2. J Hepatol. 2008. PMID: 18682313
Similar articles
-
Market uptake of new antiviral drugs for the treatment of hepatitis C.J Hepatol. 2008 Oct;49(4):528-36. doi: 10.1016/j.jhep.2008.04.021. Epub 2008 Jun 2. J Hepatol. 2008. PMID: 18682313
-
The economics of hepatitis C virus.Clin Liver Dis. 2006 Nov;10(4):717-34. doi: 10.1016/j.cld.2006.08.026. Clin Liver Dis. 2006. PMID: 17164114 Review.
-
Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):76-8. doi: 10.1038/nrgastro.2012.247. Epub 2013 Jan 8. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23296251 Review. No abstract available.
-
UNITAID can address HCV/HIV co-infection.Lancet. 2013 Feb 23;381(9867):628. doi: 10.1016/S0140-6736(13)60346-3. Lancet. 2013. PMID: 23439101 No abstract available.
-
Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.J Viral Hepat. 2008 Apr;15(4):293-9. doi: 10.1111/j.1365-2893.2007.00943.x. J Viral Hepat. 2008. PMID: 18307591
Cited by
-
Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.Eur J Public Health. 2017 Apr 1;27(2):302-306. doi: 10.1093/eurpub/ckw100. Eur J Public Health. 2017. PMID: 27542982 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
